WO2025012029 - THERAPEUTIC COMBINATION COMPRISING 4-(4-METHYL-PIPERAZIN-1-YL)-N-{6-[2-(4-TRIFLUOROMETHYL-BENZYLOXY)-ETHOXY]-1H-INDAZOL-3-YL}-BENZAMIDE AND AN ANTINEOPLASTIC AGENT
National phase entry is expected:
Publication Number
WO/2025/012029
Publication Date
16.01.2025
International Application No.
PCT/EP2024/068607
International Filing Date
02.07.2024
Title **
[English]
THERAPEUTIC COMBINATION COMPRISING 4-(4-METHYL-PIPERAZIN-1-YL)-N-{6-[2-(4-TRIFLUOROMETHYL-BENZYLOXY)-ETHOXY]-1H-INDAZOL-3-YL}-BENZAMIDE AND AN ANTINEOPLASTIC AGENT
[French]
COMBINAISON THÉRAPEUTIQUE COMPRENANT DU 4-(4-MÉTHYL-PIPÉRAZIN-1-YL)-N-6-[2-(4-TRIFLUOROMÉTHYL-BENZYLOXY)-ÉTHOXY]-1H-INDAZOL-3-YL}-BENZAMIDE ET UN AGENT ANTINÉOPLASIQUE
Applicants **
NERVIANO MEDICAL SCIENCES S.R.L.
Viale Pasteur, 10
20014 Nerviano (MI), IT
Inventors
CIOMEI, Marina
Molinetto di Lorenteggio n.15/T05
20094 Corsico (MI), IT
ARDINI, Elena
Viale Morelli, 19
20099 Sesto San Giovanni (MI), IT
Priority Data
23184767.4
11.07.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1231 | |
| EPO | Filing, Examination | 6009 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3910 |
Total: 12316 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides a therapeutic combination comprising (a) a compound of formula (I) or a pharmaceutically acceptable salt thereof, or any hydrate, crystalline form thereof and (b) one or more antineoplastic agents selected from the group consisting of demethylating agents, antimetabolite agents, BCL2 family inhibitors, immune checkpoint inhibitors and anthracyclines. The combinations are described for use in the treatment of cancer.[French]
La présente invention concerne une combinaison thérapeutique comprenant (a) un composé de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, ou tout hydrate, toute forme cristalline de celui-ci et (b) un ou plusieurs agents antinéoplasiques choisis dans le groupe constitué par des agents de déméthylation, des agents antimétabolites, des inhibiteurs de la famille BCL2, des inhibiteurs de point de contrôle immunitaire et des anthracyclines. Les combinaisons sont décrites pour être utilisées dans le traitement du cancer.